Catalyst
Slingshot members are tracking this event:
Recro Pharma (REPH) Presents Phase 3 Results Evaluating IV Meloxicam in Serious Acute Pain
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REPH |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 28, 2016
Related Projects
- With another successful trial for Meloxicam in post operative pain, where could the drug fit into the treatment landscape? REPH, INSY Executed On: Dec 02, 2016 at 10:30 AM EST
Related Keywords
Phase 3, Iv, Meloxicam, Serious Acute Pain
